Effects of GH and Lirglutide on AgRP

NCT05681299

Status	RECRUITING
Phase	Phase 4
Sponsor	Columbia University
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (14)

- HEALTHY SUBJECTS
- healthy subjects, 20 male, 20 female, ages 18-45 yr.: (i) 20 (10 male, 10 female) who are overweight/Class 1 Obese (BMI 25-34.9) with abdominal fat accumulation (central adiposity) defined by waist circumference (WC) e 102 cm in men, e 88 cm in women, except in East/South Asians for whom the criteria will be WC e 90 men and e 80 women; (ii) 20 (10 male,10 female) who are lean (BMI 19-24.9) and not meeting these WC criteria.
- No medical conditions except being overweight/obese in half of subjects
- No prescription medication or other drug use
- On screening testing: BP\<140/\<90 mmHg, HbA1c\<5.7%, FPG\<100 mg/dL, normal IGF-1 and TSH levels.

... and 9 more (see full listing online)

Exclusion (11)

- HEALTHY SUBJECTS
- History of malignancy, diabetes, thyroid cancer or pancreatitis
- Recent dieting, weight change \>5%, pregnancy or lactation or heavy exercise
- Use of glucocorticoids, hormonal supplements or medications that could affect GH or IGF-1 or for weight loss within 6 months of enrollment
- GH DEFICIENT SUBJECTS

... and 6 more (see full listing online)

Locations (1 total)

Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center, New York, New York, United States